Patent · US Active

QTY FC fusion receptor proteins

US11401320B2 · kind B2 · utility

1Cited by

5References

3Claims

0Family size

Assignees

Massachusetts Institute of Technology · US
Avalon GloboCare Corp. · US

Inventors

Shuguang Zhang · Lexington, US
David Jin · Staten Island, US
Rui Qing · Somerville, US
Uwe Sleytr · Wien, AT

Key dates

Filing date	Mar 24, 2021
Grant date	Aug 2, 2022
Priority date	—
Expiry date	Mar 24, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to QTY CCR9 and CXCR2 variant Fc receptor fusion proteins, methods for the preparation thereof and methods of use thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.